Bladder Cancer, Bladder Cancer Stage I, Bladder Cancer Stage II
Conditions
Keywords
bladder cancer, variant histology, neoadjuvant therapy, radical cystectomy
Brief summary
The World Health Organization 2016 bladder tumor classification reported that the diagnosis of variant histology has increased from 6% to 33% in the last 2 decades, and there is an increasing interest in investigating the effects on disease management, treatment options, and survival outcomes in bladder tumors with variant histology. In bladder tumors, variant histology is known to be more aggressive and has a worse prognosis than pure urothelial cancer, and most cases are muscle invasive at diagnosis. Neoadjuvant cisplatin-containing combination chemotherapy is known to improves overall survival in patients with urothelial cancers. However, it is unclear whether patients with non-pure urothelial cancer (variant) histology will also benefit from neoadjuvant chemotherapy. The investigators aimed to evaluate the role of Neoadjuvant cisplatin-containing combination chemotherapy in the final treatment plan and its impact on survival in patients with bladder cancer who were diagnosed with variant histology in the radical cystectomy specimen.
Interventions
DRUGCisplatin
Neoadjuvant cisplatin-containing combination chemotherapy was defined as the receipt of multiagent systemic chemotherapy initiated within 6 months prior to the date of radical cystectomy
Sponsors
Ankara Etlik City Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patients with squamous cell, micropapillary, nested variant, sarcomatoid, neuroendocrine, or plasmacytoid variant histology * Patients who were non-metastatic at diagnosis * Patients who completed staging and demographic data, * Patients with pathological stage (p)T2 or high grade pT1, clinical stage (c)N0 or cN1, and underwent radical cystectomy
Exclusion criteria
* Although RC histopathology was variant histology, patients in whom variant histology was not detected in previously transurethral resection bladder pathology * Patients who received therapies other than radical cystectomy (intravesical bacillus-calmette-guerin or chemotherapy) were excluded from the study. * Patients with a concomitant diagnosis of upper urinary tract urothelial carcinoma * Patients with histopathologically pure urothelial carcinoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in survival outcomes at postoperative 2-year follow-up in patients with variant histology who received neoadjuvant chemotherapy before radical cystectomy. | 2 years from radical cystectomy surgery |
Secondary
| Measure | Time frame |
|---|---|
| Factors associated with worse survival outcomes in cox-regression analysis at 2-year follow-up of all patients with variant histology who underwent radical cystectomy. | 2 years from radical cystectomy surgery |
Countries
Turkey (Türkiye)
Outcome results
None listed